girl with leukaemia lying in hospital bed
HER2 breast cancer patients! 6% complete remission 54.9% shrinkage with Trastuzumab Deruxtecan, DS-8201
When was it reported? The outcome of the phase II, multicenter, open-label, single-arm DESTINY-Breast trial was reported at the 2019 San Antonio Breast Cancer Symposium, SABCS, from December 10 –…